CLINICAL TRIALS PROFILE FOR EPINEPHRINE
✉ Email this page to a colleague
All Clinical Trials for EPINEPHRINE
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00000290 ↗ | Stress Hormones and Human Cocaine Use - 7 | Completed | University of Minnesota | Phase 1 | 1997-05-01 | The purpose of this study is to determine the HPA axis and adrenergic system activation in response to cocaine administration. |
| NCT00000290 ↗ | Stress Hormones and Human Cocaine Use - 7 | Completed | University of Minnesota - Clinical and Translational Science Institute | Phase 1 | 1997-05-01 | The purpose of this study is to determine the HPA axis and adrenergic system activation in response to cocaine administration. |
| NCT00000290 ↗ | Stress Hormones and Human Cocaine Use - 7 | Completed | National Institute on Drug Abuse (NIDA) | Phase 1 | 1997-05-01 | The purpose of this study is to determine the HPA axis and adrenergic system activation in response to cocaine administration. |
| NCT00001724 ↗ | Local Flurbiprofen to Treat Pain Following Wisdom Tooth Extraction | Completed | National Institute of Dental and Craniofacial Research (NIDCR) | Phase 2 | 1997-11-01 | This study will evaluate the effectiveness of the non-steroidal anti-inflammatory drug flurbiprofen (Ansaid® (Registered Trademark)) in relieving pain following oral surgery. Flurbiprofen is approved by the Food and Drug Administration for treatment of arthritis pain. Patients 16 years of age and older requiring third molar (wisdom tooth) extraction may be eligible for this study. Patients will undergo oral surgery to remove two lower third molar teeth. Before surgery, they will be given a local anesthetic (lidocaine with epinephrine) injected in the mouth and a sedative (Versed) infused through a catheter (thin plastic tube) placed in an arm vein. At the time of surgery, patients will also be given flurbiprofen or a placebo formulation (look-alike substance with no active ingredient) directly into the extraction site and a capsule that also may contain flurbiprofen or placebo. One in seven patients will receive only placebo. All patients will fill out pain questionnaires and stay in the clinic for up to 6 hours for observation of bleeding and medication side effects. Patients who do not have satisfactory pain relief from the test medicine after surgery may request a standard pain reliever. A small blood sample will be collected during surgery and at 15 minutes, one-half hour and 1, 2, 3, 4, 5, 6, 24 and 48 hours after surgery to measure flurbiprofen blood levels. A total of 33 ml (about 2 tablespoons) of blood will be drawn for these tests. Samples collected on the day of surgery will be drawn from the catheter used to administer the sedative; the 24- and 48-hour samples will be taken by needle from an arm or hand vein. Urine samples will also be collected between 4 and 6 hours after surgery and again at 24 and 48 hours after surgery. |
| NCT00002659 ↗ | Cisplatin Plus Epinephrine in Treating Patients With Recurrent or Refractory Head and Neck Cancer | Unknown status | Matrix Pharmaceutical | Phase 3 | 1995-05-01 | RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. It is not yet known if treatment with cisplatin plus epinephrine is effective for head and neck cancer. PURPOSE: Randomized double-blinded phase III trial to determine the effectiveness of cisplatin plus epinephrine in injectable gel form in treating patients who have recurrent or refractory head and neck cancer. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for EPINEPHRINE
Condition Name
Clinical Trial Locations for EPINEPHRINE
Trials by Country
Clinical Trial Progress for EPINEPHRINE
Clinical Trial Phase
Clinical Trial Sponsors for EPINEPHRINE
Sponsor Name
